14 completed, 12 unknown, 5 terminated, 4 recruiting. 40 Phase 2, 12 Phase 3, 8 Phase 1.
Follow Keratoconus: new trials by email Literature Review of Keratoconus trials Research Report on Keratoconus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TN-001 Topical Eyedrops for Keratoconus Low-dose TGF-B3 and Dexamethasone Sodium Phosphate, High-dose TGF-B3 and Dexamethasone Sodium Phosphate - Keratoconus | Phase 1 / Phase 2 | Enrolling by invitation | TheiaNova Ltd. | 20 | 2025-12-23 | 2026-02-04 |
| Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconus | Phase 2 | Recruiting | Glaukos Corporation | 100 | 2025-12-23 | 2026-02-10 |
| Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light - Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Recruiting | Price Vision Group | 500 | 2025-10-01 | 2026-09-25 |
| Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops - Keratoconus | Phase 1 / Phase 2 | Enrolling by invitation | Maanasa Indaram, MD | 20 | 2025-04-11 | 2026-09-11 |
| Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning PXL Platinum 330 system - Keratoconus | Phase 2 | Recruiting | Cohen Laser and Vision Center | 300 | 2024-07-01 | 2024-06-14 |
| PXL-Platinum 330 in Eyes With Corneal Thinning Conditions Pulsed or continuous lighting - Corneal Thinning, Keratoconus | Phase 1 / Phase 2 | Withdrawn | Vishal Jhanji | 2023-08-15 | 2023-10-05 | |
| Autologous Adipose-Derived Adult Stem Cell Implantation for Corneal Diseases (ADASCs-CT-CD) Implantation, Lipoaspiration - Ophthalmological Disorder, Corneal Dystrophy | Phase 2 | Completed | Vissum, Instituto Oftalmológico de Alicante | 15 | 2022-04-19 | 2023-05-06 |
| Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus NXL Energy 1, NXL Energy 2, NXL Energy 3 - Progressive Keratoconus | Phase 1 / Phase 2 | Unknown | Glaukos Corporation | 150 | 2022-03-08 | 2024-07-08 |
| The Role of Antioxidant Supplementation in Keratoconus Patients Antioxidants (Vitamins A,C,E) plus GSH, Placebo, Centrum - Keratoconus | Phase 2 | Withdrawn | University of Miami | 2021-08-01 | 2021-08-16 | |
| The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients Application of 0.02% MMC over 60 seconds post corneal crosslinking., Corneal crosslinking without the application of 0.02% MMC - Keratoconus | Phase 2 | Terminated | Ciusss de L'Est de l'Île de Montréal | 4 | 2021-07-26 | 2023-02-28 |
| Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system. - Keratoconus, Cornea Ectasia | Phase 2 | Terminated | Arbor Center for Eye Care | 11 | 2020-07-08 | 2024-12-12 |
| Safety and Effectiveness of the PXL-Platinum 330 System PXL-330 Platinum device for crosslinking with Peschke riboflavin solution - Corneal Ectasia, Keratoconus | Phase 1 / Phase 2 | Unknown | Colorado Eye Consultants/Cornea Consultants of Colorado | 300 | 2020-06-01 | 2022-01-25 |
| Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position PXL 330 Platinum device/Riboflavin - Keratoconus, Unstable, Ectasia Corneal | Phase 2 | Completed | Eye Specialists of Indiana | 12 | 2020-05-04 | 2024-08-29 |
| The Additional Role of Supplemental Oxygen Therapy in Accelerated Corneal Collagen Cross-linking in Progressive Keratoconus. A Randomized Clinical Trial perform corneal collagen cross linking accelerated and delivery of systemic oxygen, perform corneal collagen cross linking accelerated and without additional oxygen therapy, perform Conventiona corneal collagen cross linking - Keratoconus | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 30 | 2020-01-01 | 2020-04-13 |
| Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia PXL-330 Platinum device for crosslinking with Peschke riboflavin solution - Keratoconus, Pellucid Marginal Corneal Degeneration | Phase 2 | Recruiting | Goodman Eye Center | 500 | 2019-10-19 | 2025-10-20 |
| Comparison of Standard vs. Accelerated Corneal Crosslinking riboflavin 0.1%, Riboflavin 0.1% - Keratoconus, Ectasia Corneal | Phase 2 / Phase 3 | Completed | Price Vision Group | 508 | 2019-04-16 | 2026-09-17 |
| Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients IVMED-80, Placebo - Keratoconus, Corneal Ectasia | Phase 1 / Phase 2 | Completed | iVeena Delivery Systems, Inc. | 38 | 2019-02-08 | 2022-02-15 |
| Endothelial Cell Loss After Penetrating Keratoplasty PKP - Keratoconus | Phase 2 / Phase 3 | Completed | Alexandria University | 8 | 2018-07-01 | 2020-07-07 |
| Effects of Corneal Anatomical Match Between Donor and Recipient During DALK Surgery on Final Visual and Refractive Outcomes in Patients With KCN After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea, : After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea - Keratoconus | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 52 | 2018-06-01 | 2019-10-17 |
| Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study Dexamethasone implant OZURDEX - Keratoconus, Fuchs' Endothelial Dystrophy | Phase 2 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 14 | 2017-01-10 | 2019-08-16 |
Showing 20 of 40. Sign in to see all of them.
Corneal Diseases (7) · Dilatation, Pathologic (6) · Eye Diseases (3) · Corneal Dystrophies, Hereditary (1) · Corneal Dystrophy, Congenital Stromal (1) · Corneal Neovascularization (1) · Fuchs' Endothelial Dystrophy (1)
Eye Diseases (37) · Corneal Diseases (33) · Pathological Conditions, Signs and Symptoms (7) · Pathological Conditions, Anatomical (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Corneal Dystrophies, Hereditary (1) · Metaplasia (1) · Neovascularization, Pathologic (1) · Pathologic Processes (1)
Riboflavin (11) · Corneal Cross-Linking (3) · Drug Implants (2) · Ophthalmic Solutions (2) · Antioxidants (1) · Calcium Dobesilate (1) · Flavin Mononucleotide (1) · Heart Rate (1) · Hypromellose Derivatives (1) · Lubricant Eye Drops (1) · Radiation (1) · Radiotherapy (1) · Subgingival Curettage (1) · Tomography, Optical Coherence (1) · dexamethasone 21-phosphate (1)
Price Vision Group (3) · Shahid Beheshti University of Medical Sciences (3) · Cxlusa (2) · Glaukos Corporation (2) · Alexandria University (1) · Arbor Center for Eye Care (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Ciusss de L'Est de l'Île de Montréal (1) · Cohen Laser and Vision Center (1) · Colorado Eye Consultants/Cornea Consultants of Colorado (1) · Emory University (1) · Eye Specialists of Indiana (1) · Federal University of São Paulo (1) · Goodman Eye Center (1) · Instituto de Olhos de Goiania (1)
United States (21) · Iran (5) · Brazil (2) · Norway (2) · Australia (1) · Austria (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Mexico (1) · Spain (1)
Aleksandar Stojanovic, MD (2) · Arturo Chayet, MD (1) · Balamurali K. Ambati, MD, PhD (1) · Behrooz Rahimi, MD (1) · Belquiz A Nassaralla, MD PhD (1) · David Lubeck, MD (1) · Ehab Mossallam, PhD (1) · Ellen Koo, M.D. (1) · Ezra Maguen, M.D. (1) · Fateme Alipour, MD (1) · Francis Price, MD (1) · Francis W Price, Jr., MD (1) · Francis W Price, MD (1) · Gregg J Berdy, MD, FACS (1) · James J Reidy, M.D. (1)
PMID 16765803, PMID 12719068, PMID 16952090, PMID 20138607, PMID 16565005, PMID 16900027, PMID 17457183, PMID 17457184, PMID 17531694, PMID 17720054, PMID 17760642, PMID 18053900, PMID 18471635, PMID 18811118, PMID 20164744, PMID 22633357, PMID 23347367, PMID 25050368, PMID 25055145, PMID 25365551, PMID 25532633, PMID 25538907, PMID 26194634, PMID 26491663, PMID 26703505, PMID 27899371, PMID 28486314, PMID 29103962, PMID 29203068, PMID 30772348, PMID 32301973, PMID 33164825, PMID 33181549, PMID 33252568, PMID 33591032, PMID 33708786, PMID 34426402, PMID 36173242, PMID 41126474
2016 (1), 2018 (1)